Men with prostate cancer
could ultimately benefit from CCS1477 annually
Patients with blood cancers
multiple myeloma, AML, lymphomas
investigated over time by the CellCentric team
Drug prioritised, advanced
CCS1477 in the clinic, for multiple indications
The company is supported by a strong network of clinical, scientific and commercial advisors. CellCentric also actively collaborates with a number of world-leading cancer research centres on the effects of CCS1477 and p300/CBP inhibition.